SG11201807784SA - 3-desoxy derivative and pharmaceutical compositions thereof - Google Patents
3-desoxy derivative and pharmaceutical compositions thereofInfo
- Publication number
- SG11201807784SA SG11201807784SA SG11201807784SA SG11201807784SA SG11201807784SA SG 11201807784S A SG11201807784S A SG 11201807784SA SG 11201807784S A SG11201807784S A SG 11201807784SA SG 11201807784S A SG11201807784S A SG 11201807784SA SG 11201807784S A SG11201807784S A SG 11201807784SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- perugia
- cpd
- suite
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306914P | 2016-03-11 | 2016-03-11 | |
| PCT/US2017/021194 WO2017156024A1 (en) | 2016-03-11 | 2017-03-07 | 3-desoxy derivative and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807784SA true SG11201807784SA (en) | 2018-10-30 |
Family
ID=59787771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807784SA SG11201807784SA (en) | 2016-03-11 | 2017-03-07 | 3-desoxy derivative and pharmaceutical compositions thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10815267B2 (enExample) |
| EP (1) | EP3426348B1 (enExample) |
| JP (1) | JP6892457B2 (enExample) |
| KR (1) | KR102359191B1 (enExample) |
| CN (1) | CN108883305B (enExample) |
| AR (1) | AR107864A1 (enExample) |
| AU (1) | AU2017229481B2 (enExample) |
| BR (1) | BR112018068278B1 (enExample) |
| CA (1) | CA3016875C (enExample) |
| EA (1) | EA038632B1 (enExample) |
| ES (1) | ES2874682T3 (enExample) |
| IL (1) | IL261548B (enExample) |
| MX (1) | MX384800B (enExample) |
| PH (1) | PH12018501956A1 (enExample) |
| PL (1) | PL3426348T3 (enExample) |
| PT (1) | PT3426348T (enExample) |
| SG (1) | SG11201807784SA (enExample) |
| SI (1) | SI3426348T1 (enExample) |
| TW (1) | TWI772289B (enExample) |
| WO (1) | WO2017156024A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017009657A2 (pt) | 2014-11-06 | 2018-01-23 | Enanta Pharmaceuticals, Inc | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos |
| RU2017121457A (ru) | 2014-11-26 | 2018-12-26 | Энанта Фармасьютикалс, Инк. | Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| AU2016219266A1 (en) | 2015-02-11 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| RU2712099C2 (ru) | 2015-03-31 | 2020-01-24 | Энанта Фармасьютикалс, Инк. | Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения |
| EP3359160B1 (en) | 2015-10-07 | 2021-08-25 | Intercept Pharmaceuticals, Inc. | Farnesoid x receptor modulators |
| US10364267B2 (en) | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| EA038632B1 (ru) | 2016-03-11 | 2021-09-27 | Интерсепт Фармасьютикалз, Инк. | 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr) |
| AU2017368069B2 (en) | 2016-11-29 | 2021-07-08 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| MX388300B (es) | 2017-04-07 | 2025-03-19 | Enanta Pharm Inc | Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CA3201686A1 (en) * | 2021-01-14 | 2022-07-21 | Fabiola Terzi | Method for treating chronic kidney diseases |
| WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
| KR20250006156A (ko) * | 2022-04-21 | 2025-01-10 | 인터셉트 파마슈티컬즈, 인크. | 파르네소이드 x 수용체 효능제의 용도 |
| EP4547256A4 (en) * | 2022-07-01 | 2026-07-08 | Intercept Pharmaceuticals Inc | METHODS FOR IMPROVING COGNITIVE IMPAIRMENT USING BILE ACID DERIVATIVES |
| WO2024097247A1 (en) * | 2022-10-31 | 2024-05-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005089316A2 (en) * | 2004-03-12 | 2005-09-29 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using fxr ligands |
| WO2012047495A2 (en) * | 2010-09-27 | 2012-04-12 | Kythera Biopharmaceuticals, Inc. | Methods for preparing synthetic bile acids and compositions comprising the same |
| CN110041399B (zh) | 2011-12-29 | 2023-12-12 | 诺沃—诺迪斯克有限公司 | 包含非成蛋白质性的氨基酸的二肽 |
| CN105377870B (zh) * | 2013-05-14 | 2018-04-03 | 英特塞普特医药品公司 | 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物 |
| SI3626725T1 (sl) | 2014-05-29 | 2023-04-28 | Bar Pharmaceuticals S.R.L. | Derivati holana za uporabo pri zdravljenju in/ali preprečevanju bolezni, posredovanih s FXR in TGR5/GPBAR1 |
| EP3331896A4 (en) | 2015-08-07 | 2019-08-14 | Intercept Pharmaceuticals, Inc. | PROCESS FOR THE PRODUCTION OF GALLENIC ACID AND DERIVATIVES THEREOF |
| EA038632B1 (ru) | 2016-03-11 | 2021-09-27 | Интерсепт Фармасьютикалз, Инк. | 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr) |
-
2017
- 2017-03-07 EA EA201892007A patent/EA038632B1/ru unknown
- 2017-03-07 MX MX2018010983A patent/MX384800B/es unknown
- 2017-03-07 SG SG11201807784SA patent/SG11201807784SA/en unknown
- 2017-03-07 SI SI201730776T patent/SI3426348T1/sl unknown
- 2017-03-07 KR KR1020187028967A patent/KR102359191B1/ko active Active
- 2017-03-07 WO PCT/US2017/021194 patent/WO2017156024A1/en not_active Ceased
- 2017-03-07 JP JP2018547355A patent/JP6892457B2/ja active Active
- 2017-03-07 AU AU2017229481A patent/AU2017229481B2/en active Active
- 2017-03-07 CA CA3016875A patent/CA3016875C/en active Active
- 2017-03-07 US US15/451,818 patent/US10815267B2/en active Active
- 2017-03-07 CN CN201780018432.7A patent/CN108883305B/zh active Active
- 2017-03-07 EP EP17763922.6A patent/EP3426348B1/en active Active
- 2017-03-07 PT PT177639226T patent/PT3426348T/pt unknown
- 2017-03-07 PL PL17763922T patent/PL3426348T3/pl unknown
- 2017-03-07 ES ES17763922T patent/ES2874682T3/es active Active
- 2017-03-07 BR BR112018068278-0A patent/BR112018068278B1/pt active IP Right Grant
- 2017-03-09 TW TW106107817A patent/TWI772289B/zh active
- 2017-03-13 AR ARP170100619A patent/AR107864A1/es unknown
-
2018
- 2018-09-03 IL IL261548A patent/IL261548B/en active IP Right Grant
- 2018-09-06 US US16/124,122 patent/US20190002493A1/en not_active Abandoned
- 2018-09-11 PH PH12018501956A patent/PH12018501956A1/en unknown
-
2020
- 2020-09-18 US US17/025,475 patent/US11319337B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810872UA (en) | Composition and method for reducing neutropenia | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201901925RA (en) | Methods of treating acute kidney injury | |
| SG11201807023QA (en) | Compositions and methods for preventing and/or treating vitamin b12 deficiency |